Extended Data Fig. 1: Study description and qualitative comparison to modern RCC adjuvant trials. | Nature

Extended Data Fig. 1: Study description and qualitative comparison to modern RCC adjuvant trials.

From: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

Extended Data Fig. 1

a, CONSORT diagram describing screening, enrollment, vaccine manufacturing, and treatment. b, Kaplan-Meier plots of disease-free survival from the current PCV study (left) and two recent, randomize phase III adjuvant immune checkpoint inhibitor trials in RCC with similar eligibility criteria, (middle) the IMmotion-010 trial of atezolizumab vs placebo, and (left) the KEYNOTE-564 of pembrolizumab vs placebo.

Back to article page